Home » Posts tagged 'proton beam therapy'
Tag Archives: proton beam therapy
Radiation for Mesothelioma: Could Proton Therapy Be the Answer? – Advanced Oncotherapy #AVO
Researchers at the Maryland Proton Therapy Treatment Center say that a highly-targeted version of proton beam radiation could be the future of radiotherapy for malignant plural mesothelioma.
Advanced Oncotherapy #AVO, is developing a unique, fully integrated, proton therapy system. The LIGHT System is expected to be the first commercially available linear proton accelerator for medical treatment of cancer patients.
Link to the full Directors Talk article at the link below.
Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy
Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
Author information Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Abstract
PURPOSE:
To compare heart and cardiac substructure radiation exposure using intensity-modulated radiotherapy (IMRT) vs. proton beam therapy (PBT) for patients with mid- to distal esophageal cancer who received chemoradiation therapy.
METHODS AND MATERIALS:
We identified 727 esophageal cancer patients who received IMRT (n=477) or PBT (n=250) from March 2004 to December 2015. All patients were treated to 50.4Gy with IMRT or to 50.4 cobalt Gray equivalents with PBT. IMRT and PBT dose-volume histograms (DVHs) of the whole heart, atria, ventricles, and four coronary arteries were compared. For PBT patients, passive scattering proton therapy (PSPT; n=237) and intensity-modulated proton therapy (IMPT; n=13) DVHs were compared.
RESULTS:
Compared with IMRT, PBT resulted in significantly lower mean heart dose (MHD) and heart V5, V10, V20, V30, and V40as well as lower radiation exposure to the four chambers and four coronary arteries. Compared with PSPT, IMPT resulted in significantly lower heart V20, V30, and V40 but not MHD or heart V5 or V10. IMPT also resulted in significantly lower radiation doses to the left atrium, right atrium, left main coronary artery, and left circumflex artery, but not the left ventricle, right ventricle, left anterior descending artery, or right coronary artery. Factors associated with lower MHD included PBT (P<0.001), smaller planning target volume (PTV; P<0.001), and gastroesophageal junction (GEJ) tumor (P<0.001). Among PBT patients, factors associated with lower MHD included IMPT (P=0.038), beam arrangement other than AP/PA (P<0.001), smaller PTV (P<0.001), and GEJ tumor (P<0.001).
CONCLUSIONS:
In patients with mid- to distal esophageal cancer, PBT results in significantly lower radiation exposure to the whole heart and cardiac substructures than IMRT. Long-term studies are necessary to determine how this cardiac sparing effect impacts the development of coronary artery disease and other cardiac complications.
Original article here
Advanced Oncotherapy #AVO – Hardman & Co Research: Confidence greatly boosted
Confidence greatly boosted: Advanced Oncotherapy (AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on track with its development plan. Confidence has been enhanced significantly with integration of the first three structures and overcoming the technical challenge of accelerating the proton beam. Meanwhile, construction of the Harley Street site is on schedule for completion in 1H 2018, and new financing and distribution arrangements add further to confidence about the whole project.
Please click here for the full report:
|
To contact us: Hardman & Co Follow us on Twitter@HardmanandCo |
Contacts: Dr Martin Hall +44 20 7194 7622 |
mh@hardmanandco.com |
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies’ profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Hardman & Co research – Advanced Oncotherapy (AVO), technology advances & stronger balance sheet
AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction of its Harley Street site well underway and on schedule, with the site expected to be ready for installation by end 1H’19.
While the interim results provide a commercial and financial update, AVO continues its progress in accelerating the proton beam and is on-track in building a machine capable of treating superficial tumours by 3Q’18. The financing has been on a rocky road but confidence is building up as the proton accelerates.
2017 interim results
Successful integration of the different modules of the LIGHT system highlight the reduced technical risk inherent to the development of the LIGHT accelerator. All the different components have been tested individually, and more units are successfully being integrated. To date, three – the proton source, the RFQ and the first SCDTL – of the four main structures have been integrated and the proton beam generated and accelerated up to an energy of 7.5MeV, which is a major achievement. The fourth element – the CCL(s) – has been received at the Geneva testing facility and are less technically challenging to integrate as they have already been validated by the LIBO prototype, which was a high-speed unit that has already been integrated (with another accelerator).
Link here to full research note
Three ways to make proton therapy affordable – Nature Weekly Journal
Three ways to make proton therapy affordable – Nature Weekly Journal
by Thomas R Bortfeld & Jay S Loeffler
If cost was not an issue, proton therapy would be the treatment of choice for most patients with localized tumours. Protons can be targeted more precisely than X-rays1, so the tissues around the tumour receive two to three times less radiation. This lowers the chance of causing secondary tumours2 or impairing white blood cells and the immune system3. High doses of protons can be delivered safely to hard-to-treat tumours: for instance, those at the base of the skull or in the liver. Such accuracy is crucial when treating cancers in children.
Yet most hospitals do not offer proton therapy. The equipment is huge and expensive. Housed in multistorey buildings with halls the size of tennis courts, one proton centre with 2–3 treatment rooms typically costs more than US$100 million to build. To reach deep-seated tumours, the protons must be sped up to 60% of the speed of light (a kinetic energy of 235 megaelectronvolts; MeV) using a particle accelerator, such as a cyclotron or synchrotron. Rotatable gantries with wheels typically 10 metres across and weighing 100–200 tonnes direct the protons at the patient from a range of angles. Concrete shields, metres thick, are necessary to block stray neutrons.
“Nothing so big and so useless has ever been discovered in medicine,” said Amitabh Chandra, director of health policy research at the John F. Kennedy School of Government at Harvard University in Cambridge, Massachusetts. He has compared a proton-therapy system to the Death Star from Star Wars.
Nonetheless, there are now more than 60 proton-therapy centres around the world, with 26 in the United States alone. Almost half of them (12) treated their first patient within the past three years. But construction delays and closures are also common. The companies that build the facilities and the investment groups that own them are increasingly struggling to make a profit. The Scripps Proton Therapy Center in San Diego, California, filed for bankruptcy in March, just three years after opening its doors.
What has gone wrong? Patient charges are high, often three to four times more than the priciest X-ray treatments. Fewer patients are being treated with protons than was anticipated: common diseases such as prostate cancer can be cured as effectively using other forms of radiation and surgery4. And in the United States, major insurance companies are denying proton therapy to up to 30% of eligible patients5 on the basis that there are too few rigorously designed and completed clinical trials providing evidence of better outcomes. In our experience, however, this is a vicious cycle: such trials are difficult to conduct when patients are denied private health coverage5.
The solution is to make proton-therapy facilities smaller and cheaper, with costs of around $5 million to $10 million, similar to high-end X-ray systems. A dozen ‘miniaturized’ facilities are in operation. We have installed one at Massachusetts General Hospital in Boston. Now academics, private researchers and investors need to make proton-therapy systems even smaller and more competitive so that more patients can benefit.
Shrinking infrastructure
Proton-therapy technology is much more compact today than it was a few decades ago6. Superconducting magnets can confine protons in a tighter space. The weight of accelerators has gone down from hundreds of tonnes to less than 20, and their diameters have shrunk by a factor of 3 since the early 1990s. The smallest therapeutic accelerator so far is less than 2 metres in diameter — about the same footprint as a king-sized bed.
Yet, combined with the gantry and other equipment needed, even the most compact systems for sale today occupy a couple of hundred square metres. This is much larger than a conventional treatment room of 50 square metres. Most hospitals lack the money and space to construct a special building for proton therapy.
We have been testing how smaller systems can be squeezed into existing hospital buildings, working with the proton-technology vendor ProTom International in Wakefield, Massachusetts, and engineers at the Massachusetts Institute of Technology in Cambridge. Getting an accelerator and gantry into two basement X-ray rooms in our central Boston hospital cost about $30 million, less than one-third of the cost of a dedicated centre but still about five times more than a top-end X-ray unit.
Both the equipment and the price tag need to shrink further if proton therapy is to replace X-rays. Fitting the facility into one room is the goal. This would allow hospitals to simply replace existing X-ray equipment with proton units without building work. Getting there will be technically challenging, even with rapid advances in magnets
Full article here
Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers, Start of Treatment, Specifications & Company Analysis – Global Forecast to 2022
ReportsWorldwide has announced the addition of a new report title Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers, Start of Treatment, Specifications & Company Analysis – Global Forecast to 2022 to its growing collection of premium market research reports.
The continuing exploration of the benefits of proton therapy is inspiring a growing and massive construction of new proton centers globally. Proton therapy is an advanced form of radiation therapy that uses high-energy proton beam rather than conventional radiotherapy to irradiate a tumor. The main advantage of proton therapy is that while destroying the target malignant cells, it causes minimal damage to the surrounding cells. Proton therapy uses the ionization technique to inhibit cell proliferation. Protons move slowly through the body and interact with electrons and discharge energy.
Globally, the numbers of patients treated with Proton Therapy is very low whereas; the potential candidates for proton therapy are in Millions. The number of proton therapy centers is increasing globally. Still, industry experts believe that players will miss out on a majority of cancer patients who can benefit with proton therapy, overlooking a huge multi-Billion-dollar potential market. IBA dominates the proton therapy market globally. However, other players like Varian, Mitsubishi, Mevion, Hitachi etc. have also started to make their presence felt in the market.
The unprecedented demand of proton therapy for the treatment of cancer has set the stage for the market to move ahead at a rapid pace. It is anticipated that the Global proton therapy market will almost double by 2022 from its current market value. The increased demand for proton therapy has motivated many prominent cancer centers in the world to provide proton therapy treatment. The number of proton therapy centers worldwide is anticipated to increase year on year, which in turn, will result in more clinical research, better clinician understanding and greater patient awareness of its benefits-which will help drive the further growth.
For a Detailed description and table of contents of this report please click here: www.reportsworldwide.com/report/proton-therapy-market-act…
For full article click here
North America Radiotherapy Market by Equipment Type (Linear Accelerators, Radiation Therapy Simulators and Treatment Planning Systems)
The North America Radiotherapy Market was worth $1,798 million in 2016 and estimated to be growing at a CAGR of 5.54%, to reach $2,355 million by 2021.
(EMAILWIRE.COM, May 02, 2017 ) According to the report North America Radiotherapy Market by Type, by Application, by Equipment Type and by Region – Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)”, published by Market Data Forecast, the global market is projected to reach USD 2,355 Million by 2021, at a CAGR of 5.54% from 2016 to 2021.
Free sample for the report is available at “http://www.marketdataforecast.com/market-reports/north-america-radiotherapy-market-816/request-sample”
North America is the utmost vibrant, extremely competitive and the leading market for radiotherapy devices globally. The market growth is considerably higher in North America since it is continuously inclined to the usage of novel technologies.
Radiation therapy practiceshigh energy radiation on directed cells and cell progression to stop them from growing and distributing. Radiations are mainly from an external machine or from implants i.e. internal machine which is placed near the tumours. This technique is widely used for the treatment of cancerous tumour, benign tumours and other conditions like thyroid disease and some blood disorders.
The North American Radiotherapy Market is driven by quickly altering cancer treatment technology and increasing number of cancer patients. Growth is also driven by technological advancements in biological and molecular imaging techniques that permit radiotherapy to be progressively personalized for patient needs. Emerging healthy reimbursement plans and untapped market in few areas are also few factors fuelling the growth of radiotherapy market. Major factors inhibiting the growth of the market are healthcare expenditure and alternative treatment procedures.
Segmentation:
By Type:
• External Beam Radiation Therapy
• Intensity-Modulated Radiation Therapy (IMRT)
• Image-Guided Radiation Therapy (IGRT)
• Tomotherapy
• Stereotactic Radiosurgery
• Stereotactic Body Radiation Therapy
• Proton Therapy
• Internal Beam Radiation Therapy
• Systemic Radiation Therapy
By Application:
• Skin & Lip Cancer
• Head & Neck Cancer
• Breast Cancer
• Prostate Cancer
• Cervical Cancer
• Lung Cancer
• Spine Cancer
By Equipment Type:
• Linear Accelerators
• Radiation Therapy Simulators
• Treatment Planning Systems
Nordion Inc. (Canada), RaySearch Laboratories AB (Sweden), Ion Beam Applications SA (Belgium), C. R. Bard Inc. (U.S.), Mevion Medical Systems Inc. (U.S.), Varian Medical Systems Inc. (U.S.), IsoRay Medical Inc. (U.S.),Elekta AB (Sweden), Accuray Incorporated (U.S.), and Mitsubishi Electric Corporation (Japan) are the key players in the radiotherapy market.
The Radiotherapy market study offers the following deliverables:
• Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
• Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
• Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
• Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
• Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
• A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
• Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Therapeutics Segment:
Uterine cancer therapeutics market <||>rnhttp://www.marketdataforecast.com/market-reports/global-uterine-cancer-therapeutics-market-1489/
Scar treatment <||>rnhttp://www.marketdataforecast.com/market-reports/global-scar-treatment-market-943/
Renal diseases <||>rnhttp://www.marketdataforecast.com/market-reports/global-renal-diseases-market-1291/
Prostate cancer market <||>rnhttp://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/
Pancreatic cancer market <||>rnhttp://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Market Data Forecast
Abhishek
Tel: +1-888- 702-9626
Advanced Oncotherapy (AVO) – Investor Presentations
Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that it will be hosting investor and analyst presentations in London on Monday 6 March 2017 and in Zürich, Switzerland the following day, Tuesday 7 March 2017.
The presentations will outline some of the key aspects of Advanced Oncotherapy’s technology, the clinical benefits of proton therapy and the key milestones for the manufacturing and commercialisation of LIGHT (Linac for Image Guided Hadron Therapy). These events are in relation to the initial 100 day review that has been conducted by CEO Nicolas Serandour, as announced upon his appointment on 27 October 2016.
The event in London will be held at the Royal Society of Medicine, 1 Wimpole St, W1G 0AE.
In Zürich, it will take place at the Baur au Lac hotel, Talstrasse 1, 8001, Switzerland. Both events will commence at 4pm local time and will be followed by drinks and canapés at 5.30pm.
The timetable for the event in London is as follows:
| 15:30 | Registration
|
| 16:00 | Introduction to Advanced Oncotherapy: From the Development of a World-Leading Technology to its Commercialisation
|
| 16:20
|
The Benefit of Proton Therapy: How to Make the Best Use of Proton Therapy in Today’s Treatments
|
| 16.35 | The Advantages of the LIGHT System: Taking Advantage of a Linear Accelerator
|
| 16.50 | Roadmap to Production and Conclusions
|
| 17.05 | Q&As |
| 17.30 | Drinks & canapés |
The event in Zürich will follow the same format, excluding registration.
To register and attend either presentation, or to receive further information on Advanced Oncotherapy, please contact Walbrook PR on 020 7933 8780 or email avo@walbrookpr.com.
For further information, please contact:
| Advanced Oncotherapy plc | www.avoplc.com | ||||
| Nicolas Serandour, Chief Executive Officer | Tel: +44 20 3617 8728 | ||||
| Michael Sinclair, Executive Chairman | |||||
| Stockdale Securities (Nomad & Joint Broker) | Tel: +44 20 7601 6100 | ||||
| Antonio Bossi / David Coaten | |||||
| Stifel Nicolaus Europe (Joint Broker) | Tel: +44 20 7710 7600 | ||||
|
|||||
| Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com | ||||
| Paul McManus | Mob: +44 7980 541 893 | ||||
| Anna Dunphy | Mob: +44 7876 741 001 |
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac for Image Guided Hadron Therapy (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Advanced Oncotherapy (AVO) – Significant Shareholder
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on 7 February 2017 that Dr Nick Plowman, Chairman of the Company’s medical advisory board, became a significant shareholder on 6 June 2016 and, following subsequent share purchases, currently holds 2,636,799 ordinary shares of 25 pence each in the Company, representing 3.6% of the issued share capital of the Company.
|
Advanced Oncotherapy Plc |
|
|
Dr Michael Sinclair, Executive Chairman |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
Jonathan Senior / Ben Maddison |
Tel: +44 20 7710 7600 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Proton beam therapy used in tumour treatment in UAE – The National UAE
An advanced form of radiotherapy that reduces the risk of side effects in cancer patients will be available in the UAE for the first time when a Dh220 million health centre opens in Abu Dhabi in 2018.
Proton beam therapy, which uses protons rather than X-rays, is regarded as a safer way to treat hard-to-reach tumours because it causes less damage to surrounding tissue. It is used to treat many forms of the disease in situations where conventional options are limited and radiotherapy presents unacceptable risks to patient health, said Dr Mohanad Diab, consultant medical oncologist at NMC Specialty in Abu Dhabi.
“These situations include eye and brain cancers, tumours close to the brainstem and spinal cord, prostate, liver, lung and breast cancers, and paediatric cancers. It is very useful for children and it is used most often to treat brain tumours in young children whose brains are still developing,” he said.
The proton beam therapy centre in Al Shahamh will be part of the Gulf International Cancer Centre.
“At least 200 patients at our centre will benefit from proton beam and if we are the only centre in the area, there will be patients coming from neighbouring countries,” said Dr Aly Abdel Razek, executive director and head of radiation oncology at GICC,
Oncologists from the GICC will be sent for training to the US – where there are about 25 centres offering this treatment – to learn about the technology.
Many children will be helped by the technique, said Dr Razek. He gave an example of when doctors are treating cancer in a child’s spinal cord, proton beams treat the problem area without affecting the heart or the lungs.
“About 10 to 20 per cent of the cancer patients who receive radiation therapy can benefit from the use of proton beam.”
Proton therapy is not widely available because of its high cost. There are only a limited number of centres in the world that can deliver the treatment.
At the moment, patients in the UK who require this type of radiotherapy are sent for treatment in the US, according to Cancer Research UK.
Full article here